Current Problems in Cardiology
Volume 35, Issue 1 , Pages 8-64 , January 2010

Device Therapy and Cardiac Transplantation for End-Stage Heart Failure

References 

  1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics, 2009 update (A report from the american heart association statistics committee and stroke statistics subcommittee). Circulation. 2009;119:e21–e181
  2. Miller LW, Missov ED. Epidemiology of heart failure. Cardiol Clin. 2001;19:547–555
  3. Juonala M, Viikari JS, Rasanen L, et al. Young adults with family history of coronary heart disease have increased arterial vulnerability to metabolic risk factors: the cardiovascular risk in young Finns study. Arterioscler Thromb Vasc Biol. 2006;26:1376–1382
  4. Park SJ, Tector A, Piccioni W, et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg. 2005;129:9–17
  5. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435–1443
  6. Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory end stage heart failure. J Card Fail. 2003;9:180–187
  7. Fang J, Mensah GA, Croft JB, et al. Heart failure-related hospitalization in the U.S., 1979-2004. J Am Coll Cardiol. 2008;52:428–434
  8. Garrett N, Martini EM. The boomers are coming: a total cost of care model of the impact of population aging on the cost of chronic conditions in the United States. Dis Manag. 2007;10:51–60
  9. Kirklin JK, Naftel DC. Mechanical circulatory support registering a therapy in evolution circulation. Heart Fail. 2008;1:200–205
  10. Shumacker HB. A surgeon to remember: notes about Vladimir Demikhov. Ann Thorac Surg. 1994;58:1196–1198
  11. Marasco SF, Lukas G, McDonald M, et al. Review of ECMO (Extra Corporeal Membrane Oxygenation) support in critically ill adult patients. Heart Lung Circul. 2008;17(suppl 4):S41–S47
  12. Rajdev S, Irani A, Sharma S, et al. Clinical utility of TandemHeart for high-risk tandem procedures: percutaneous balloon aortic valvuloplasty followed by complex PCI. J Invasive Cardiol. 2007;19:E346–E349
  13. Cohen R, Domniez T, Elhadad S. High-risk left main coronary stenting supported by percutaneous Impella recover LP 2.5 assist device. J Invasive Cardiol. 2007;19:E294–E296
  14. Burzotta F, Paloscia L, Trani C, et al. Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study. J Cardiovasc Med. 2008;9:1004–1010
  15. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005;26:1276–1283
  16. Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52:1584–1588
  17. Rossiter-Thornton M, Arun V, Forrest AP, et al. Left ventricular support with the Impella LP 5.0 for cardiogenic shock following cardiac surgery. Heart Lung Circul. 2008;17:243–245
  18. Saeed D, Kizner L, Arusoglu L, et al. Prolonged transcutaneous cardiopulmonary support for postcardiotomy cardiogenic shock. ASAIO J. 2007;53:e1–e3
  19. John R, Liao K, Lietz K, et al. Experience with the Levitronix CentriMag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J Thorac Cardiovasc Surg. 2007;134:351–358
  20. De Robertis F, Rogers P, Amrani M, et al. Bridge to decision using the Levitronix CentriMag short-term ventricular assist device. J Heart Lung Transplant. 2008;27:474–478
  21. Dekkers RJ, Fitzgerald DJ, Couper GS. Five-year clinical experience with Abiomed BVS 5000 as a ventricular assist device for cardiac failure. Perfusion. 2001;16:13–18
  22. Mielniczuk L, da Silva LB, Haddad H. Enhanced external counterpulsation in ischemic heart disease and congestive heart failure. CMAJ. 2004;170:1223–1224
  23. Feldman AM, Silver MA, Francis GS, et al. Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1198–1205
  24. Feldman AM, Silver MA, Francis GS, et al. Treating heart failure with enhanced external counterpulsation (EECP): design of the prospective evaluation of EECP in heart failure (PEECH) trial. J Card Fail. 2005;11:240–245
  25. Lee CM, Wu YW, Jui HY, et al. Enhanced external counterpulsation reduces lung/heart ratio at stress in patients with coronary artery disease. Cardiology. 2006;106:237–240
  26. Abbottsmith CW, Chung ES, Varricchione T, et al. Enhanced external counterpulsation improves exercise duration and peak oxygen consumption in older patients with heart failure: a subgroup analysis of the PEECH trial. Congest Heart Fail. 2006;12:307–311
  27. Conti CR. Ongoing and planned studies of enhanced external counterpulsation. Clin Cardiol. 2002;25:II26–II28
  28. Birks EJ, Yacoub MH, Banner NR, et al. The role of bridge to transplantation: should LVAD patients be transplanted?. Curr Opin Cardiol. 2004;19:148–153
  29. Ekser B, Rigotti P, Gridelli B, et al. Xenotransplantation of solid organs in the pig-to-primate model. Transpl Immunol. 2008;21:87–92
  30. McCarthy PM, James KB, Savage RM, et al. Implantable left ventricular assist device (Approaching an alternative for end-stage heart failure. Implantable LVAD Study Group). Circulation. 1994;90:II83–II86
  31. Nose Y. Implantable total artificial heart developed by Abiomed gets FDA approval for clinical trials. Artif Organs. 2001;25:429
  32. Kantrowitz A, Krakauer J, Sherman JL. A permanent mechanical auxiliary ventricle: experimental and clinical experience. J Cardiovasc Surg. 1968;9:1–16
  33. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007;116:497–505
  34. Hunt SA. Mechanical circulatory support: new data, old problems. Circulation. 2007;116:461–462
  35. Stevenson LW, Miller LW, Desvigne-Nickens P, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation. 2004;110:975–981
  36. Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol. 2007;50:741–747
  37. Radovancevic B, Vrtovec B, de Kort E, et al. End-organ function in patients on long-term circulatory support with continuous- or pulsatile-flow assist devices. J Heart Lung Transplant. 2007;26:815–818
  38. Houghton P. Living with the Jarvik 2000: a five-plus year experience. Artif Organs. 2006;30:322–323
  39. Pae WE, Connell JM, Adelowo A, et al. Does total implantability reduce infection with the use of a left ventricular assist device? (The LionHeart experience in Europe). J Heart Lung Transplant. 2007;26:219–229
  40. Dang NC, Topkara VK, Mercando M, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant. 2006;25:1–6
  41. Matthews JC, Koelling TM, Pagani FD, et al. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51:2163–2172
  42. Slaughter MS, Tsui SS, El-Banayosy A, et al. Results of a multicenter clinical trial with the Thoratec implantable ventricular assist device. J Thorac Cardiovasc Surg. 2007;133:1573–1580
  43. Feldman CM, Khan SN, Slaughter MS, et al. Improvement in early oxygen uptake kinetics with left ventricular assist device support. ASAIO J. 2008;54:406–411
  44. Etz CD, Welp HA, Tjan TD, et al. Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg. 2007;83:1697–1705
  45. Wray J, Hallas CN, Banner NR. Quality of life and psychological well-being during and after left ventricular assist device support. Clin Transpl. 2007;21:622–627
  46. Casida J. The lived experience of spouses of patients with a left ventricular assist device before heart transplantation. Am J Crit Care. 2005;14:145–151
  47. Shapiro PA. Psychiatric aspects of cardiovascular disease. Psychiatr Clin North Am. 1996;19:613–629
  48. Zierer A, Melby SJ, Voeller RK, et al. Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. Ann Thorac Surg. 2007;84:515–520
  49. Schulman AR, Martens TP, Christos PJ, et al. Comparisons of infection complications between continuous flow and pulsatile flow left ventricular assist devices. J Thorac Cardiovasc Surg. 2007;133:841–842
  50. Letsou GV, Shah N, Gregoric ID, et al. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant. 2005;24:105–109
  51. Geisen U, Heilmann C, Beyersdorf F, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardio Thorac Surg. 2008;33:679–684
  52. Steinlechner B, Dworschak M, Birkenberg B, et al. Platelet dysfunction in outpatients with left ventricular assist devices. Ann Thorac Surg. 2009;87:131–137
  53. John R, Kamdar F, Liao K, et al. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. J Thorac Cardiovasc Surg. 2008;136:1318–1323
  54. John R, Kamdar F, Liao K, et al. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg. 2008;86:1227–1234[Discussion 1234-5]
  55. Slaughter MS, Sobieski MA, Gallagher C, et al. Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device. Tex Heart Inst J. 2008;35:245–249
  56. Guha A, Munjampalli S, Bandi V, et al. Pleural effusion after ventricular assist device placement: prevalence and pleural fluid characteristics. Chest. 2008;134:382–386
  57. Joyce LD, DeVries WC, Hastings WL, et al. Response of the human body to the first permanent implant of the Jarvik-7 total artificial heart. Trans Am Soc Artif Intern Organs. 1983;29:81–87
  58. Copeland JG, Smith RG, Arabia FA, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med. 2004;351:859–867
  59. Samuels L, Entwistle J, Holmes E, et al. Use of the AbioCor replacement heart as destination therapy for end-stage heart failure with irreversible pulmonary hypertension. J Thorac Cardiovasc Surg. 2004;128:643–645
  60. Dowling RD, Gray LA, Etoch SW, et al. Initial experience with the AbioCor implantable replacement heart system. J Thorac Cardiovasc Surg. 2004;127:131–141
  61. Meyns B, Ector J, Rega F, et al. First human use of partial left ventricular heart support with the Circulite synergy micro-pump as a bridge to cardiac transplantation. Eur Heart J. 2008;29:2582
  62. Klotz S, Barbone A, Reiken S, et al. Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties. J Am Coll Cardiol. 2005;45:668–676
  63. Barbone A, Holmes JW, Heerdt PM, et al. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure: a primary role of mechanical unloading underlying reverse remodeling. Circulation. 2001;104:670–675
  64. Heerdt PM, Holmes JW, Cai B, et al. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation. 2000;102:2713–2719
  65. Burkhoff D, Holmes JW, Madigan J, et al. Left ventricular assist device-induced reverse ventricular remodeling. Prog Cardiovasc Dis. 2000;43:19–26
  66. DiBardino DJ. The history and development of cardiac transplantation. Tex Heart Inst J. 1999;26:198–205
  67. Carrel A, Guthrie CC. Anastomosis of blood vessels by the patching method and transplantation of the kidney. 1906 (Classical article) Yale J Biol Med. 2001;74:243–247
  68. Mann FC, Priestly JT, Markowitz J, et al. Transplantation of the intact mammalian heart. Arch Surg. 1933;26:219–224
  69. Willman VL, Cooper T, Cian LG, et al. Auto-transplantation of the canine heart. Surg Gynecol Obstet. 1962;115:299–302
  70. Barnard CN. The operation (A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town). S Afr Med J. 1967;41:1271–1274
  71. Rodeheffer RJ, McGregor CG. The development of cardiac transplantation. Mayo Clin Proc. 1992;67:480–484
  72. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the international society for heart and lung transplantation (Twenty-fourth official adult heart transplant report—2007). J Heart Lung Transplant. 2007;26:769–781
  73. Taylor DO, Edwards LB, Aurora P, et al. Registry of the international society for heart and lung transplantation (Twenty-fifth official adult heart transplant report—2008). J Heart Lung Transplant. 2008;27:943–956
  74. Lietz K, Miller LW. Improved survival of patients with end-stage heart failure listed for heart transplantation: analysis of organ procurement and transplantation network/U.S. United Network of Organ Sharing data, 1990-2005. J Am Coll Cardiol. 2007;50:1282–1290
  75. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235
  76. Borkon AM, Muehlebach GF, Jones PG, et al. An analysis of the effect of age on survival after heart transplant. J Heart Lung Transplant. 1999;18:668–674
  77. Morgan JA, John R, Weinberg AD, et al. Long-term results of cardiac transplantation in patients 65 years of age and older: a comparative analysis. Ann Thorac Surg. 2003;76:1982–1987
  78. Nwakanma LU, Williams JA, Weiss ES, et al. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg. 2007;84:1556–1562[Discussion 1562-3]
  79. Zangwill S, Ellis T, Stendahl G, et al. Practical application of the virtual crossmatch. Pediatr Transplant. 2007;11:650–654
  80. Betkowski AS, Graff R, Chen JJ, et al. Panel-reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant. 2002;21:644–650
  81. Loh E, Bergin JD, Couper GS, et al. Role of panel-reactive antibody cross-reactivity in predicting survival after orthotopic heart transplantation. J Heart Lung Transplant. 1994;13:194–201
  82. Leech SH, Lopez-Cepero M, LeFor WM, et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transpl. 2006;20:476–484
  83. Lavee J, Kormos RL, Duquesnoy RJ, et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant. 1991;10:921–929[Discussion 929-30]
  84. Lenexa K. Standards for histocompatibility testing. Lenexa, Kansas: American Society for Histocompatibility and Immunogenetics; 1998;
  85. UNOS. The United Network for Organ Sharing. Standards for histocompatibility testing. 1998. ByLaws Appendix B Attachment JJA, www.unos.org/policiesandbylaws/bylaws.
  86. Shumway NE, Lower RR, Stofer RC. Transplantation of the heart. Adv Surg. 1966;2:265–284
  87. Jacquet L, Ziady G, Stein K, et al. Cardiac rhythm disturbances early after orthotopic heart transplantation: prevalence and clinical importance of the observed abnormalities. J Am Coll Cardiol. 1990;16:832–837
  88. Angermann CE, Spes CH, Tammen A, et al. Anatomic characteristics and valvular function of the transplanted heart: transthoracic versus transesophageal echocardiographic findings. J Heart Transplant. 1990;9:331–338
  89. Banner NR, Khaghani A, Fitzgerald M. The Expanding Role of Cardiac Transplantation (Assisted Circulation). Berlin: Springer-Verlag; 1989;
  90. Yacoub MH, Banner NA. Recent Development in Lung and Heart-Lung Transplantation. In: Transplantation Reviews. vol 3:Philadelphia, PA: WB Saunders; 1989;p. 1–29
  91. Aziz TM, Burgess MI, El-Gamel A, et al. Orthotopic cardiac transplantation technique: a survey of current practice. Ann Thorac Surg. 1999;68:1242–1246
  92. Drefus G, Jebara V, Mihaileaunu S, et al. Total orthotopic heart transplantation: an alternative to the standard technique. Ann Thorac Surg. 1991;52:1181–1184
  93. Sievers HH, Weyand M, Kraatz EG, et al. An alternative technique for orthotopic cardiac transplantation, with preservation of the normal anatomy of the right atrium. J Thorac Cardiovasc Surg. 1991;39:70–72
  94. Schnoor M, Schafer T, Luhmann D, et al. Bicaval versus standard technique in orthotopic heart transplantation: a systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2007;134:1322–1331
  95. Uber PA, Mehra MR. Induction therapy in heart transplantation: is there a role?. J Heart Lung Transplant. 2007;26:205–209
  96. Opelz G, Schwarz V, Henderson R, et al. Non-Hodgkin's lymphoma after kidney or heart transplantation: frequency of occurrence during the first posttransplant year. Transpl Int. 1994;7(suppl 1):S353–S356
  97. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990;323:1723–1728
  98. Higgins R, Kirklin JK, Brown RN, et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?. J Heart Lung Transplant. 2005;24:392–400
  99. Crespo-Leiro MG, Alonso-Pulpon L, Arizon JM, et al. Influence of induction therapy, immunosuppressive regimen and antiviral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry. J Heart Lung Transplant. 2007;26:1105–1109
  100. Segovia J, Rodriguez-Lambert JL, Crespo-Leiro MG, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation. 2006;81:1542–1548
  101. Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant. 2005;24:1297–1304
  102. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med. 2005;352:2705–2713
  103. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients—a large European trial. Am J Transplant. 2006;6:1387–1397
  104. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant. 2006;25:434–439
  105. Hosenpud JD, Bennett LE. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation. 2001;72:1662–1665
  106. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients (Mycophenolate Mofetil Investigators). Transplantation. 1998;66:507–515
  107. Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation. 2005;80:S235–S243
  108. Pethig K, Heublein B, Wahlers T, et al. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant. 2004;23:61–66
  109. Lietz K, John R, Schuster M, et al. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients. Transplant Proc. 2002;34:1828–1829
  110. Weigel G, Griesmacher A, Karimi A, et al. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J Heart Lung Transplant. 2002;21:1074–1079
  111. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6:1377–1386
  112. Patel JK, Kobashigawa JA. Tacrolimus in heart transplant recipients: an overview. Biodrugs. 2007;21:139–143
  113. Aguero J, Almenar L, Martinez-Dolz L, et al. Variations in the frequency and type of infections in heart transplantation according to the immunosuppression regimen. Transplant Proc. 2006;38:2558–2559
  114. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol. 1990;144:251–258
  115. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35:7S–14S
  116. Terada N, Lucas JJ, Szepesi A, et al. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol. 1993;154:7–15
  117. Morales JM, Andres A, Rengel M, et al. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 2001;16:121–124
  118. Shihab FS, Bennett WM, Yi H, et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int. 2004;65:1262–1271
  119. Kushwaha SS, Khalpey Z, Frantz RP, et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant. 2005;24:2129–2136
  120. Raichlin E, Khalpey Z, Kremers W, et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation. 2007;84:467–474
  121. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation. 2007;116:2726–2733
  122. McMullen JR, Sherwood MC, Tarnavski O, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 2004;109:3050–3055[Epub 2004 June 7]
  123. Hauck L, Harms C, Rohne J, et al. Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart. Nat Med. 2008;14:315–324[Epub 2008 March 2]
  124. Doggrell SA. Cardiovascular research in Australia. Drug News Perspect. 2003;16:540–550
  125. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847–858
  126. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation. 2007;84:1436–1442
  127. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006;81:1234–1248
  128. Bestetti R, Theodoropoulos TAD, Burdmann EA, et al. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up. Transplantation. 2006;81:692–696
  129. Groetzner J, Kaczmarek I, Landwehr P, et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardio Thorac Surg. 2004;25:333–341
  130. Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transpl. 2007;21:460–465
  131. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation. 2004;77:1555–1561
  132. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003;108:48–53
  133. Troppmann C, Pierce JL, Gandhi MM, et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation. 2003;76:426–429
  134. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58–69
  135. Yamani MH, Yousufuddin M, Starling RC, et al. Does acute cellular rejection correlate with cardiac allograft vasculopathy?. J Heart Lung Transplant. 2004;23:272–276
  136. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006;6:150–160
  137. Starling RC, Pham M, Valantine H, et al. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant. 2006;25:1389–1395
  138. Pham MX, Deng MC, Kfoury AG, et al. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the invasive monitoring attenuation through gene expression (IMAGE) trial. J Heart Lung Transplant. 2007;26:808–814
  139. Taylor DO, Yowell RL, Kfoury AG, et al. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant. 2000;19:518–521
  140. Uber WE, Self SE, Van Bakel AB, et al. Acute antibody-mediated rejection following heart transplantation. Am J Transplant. 2007;7:2064–2074
  141. Tan CD, Baldwin WM, Rodriguez ER. Update on cardiac transplantation pathology. Arch Pathol Lab Med. 2007;131:1169–1191
  142. Smith RN, Brousaides N, Grazette L, et al. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant. 2005;24:1202–1210
  143. Almuti K, Haythe J, Dwyer E, et al. The changing pattern of humoral rejection in cardiac transplant recipients. Transplantation. 2007;84:498–503
  144. Roelke M, McNamara D, Osswald S, et al. A comparison of VVIR and DDDR pacing following cardiac transplantation. Pacing Clin Electrophysiol. 1994;17:2047–2051
  145. Rothenburger M, Teerling E, Bruch C, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant. 2007;26:250–257
  146. Hertz MI, Taylor DO, Trulock EP, et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant. 2002;21:950–970
  147. Kapadia SR, Ziada KM, L'Allier PL, et al. Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging. J Heart Lung Transplant. 2000;19:167–172
  148. Boilson BA, McGregor CG. Stem cells and transplant vasculopathy. Minerra Cardioangiol. 2009;57:233–247Review
  149. Kuppahally SS, Valantine HA, Weisshaar D, et al. Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. Am J Transplant. 2007;7:2388–2395
  150. Kobashigawa JA. First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation. J Heart Lung Transplant. 2003;22:711–714
  151. Caforio AL, Tona F, Fortina AB, et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant. 2004;4:962–970
  152. Bernstein D, Kolla S, Miner M, et al. Cardiac growth after pediatric heart transplantation. (see comments) Circulation. 1992;85:1433–1439
  153. Adams DH, Russell ME, Hancock WW, et al. Chronic rejection in experimental cardiac transplantation: studies in the Lewis-F344 model. Immunol Rev. 1993;134:5–19
  154. Jimenez J, Kapadia SR, Yamani MH, et al. Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. J Heart Lung Transplant. 2001;20:393–398
  155. Brunner-La Rocca HP, Schneider J, Kunzli A, et al. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. Transplantation. 1998;65:538–543
  156. Raichlin E, Edwards B, Kremers W, et al. Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation. J Heart Lung Transplant. 2009;28:320–327
  157. Opelz G. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients (The collaborative transplant study). Transplant Proc. 1997;29:73–76
  158. Narrod J, Kormos R, Armitage J, et al. Acute rejection and coronary artery disease in long-term survivors of heart transplantation. J Heart Transplant. 1989;8:418–420[Discussion 420-1]
  159. Vassalli G, Gallino A, Weis M, et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J. 2003;24:1180–1188
  160. Yamani MH, Haji SA, Starling RC, et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol. 2002;39:970–977
  161. Stoica SC, Cafferty F, Pauriah M, et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant. 2006;25:420–425
  162. Hognestad A, Endresen K, Wergeland R, et al. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol. 2003;42:477–482
  163. Pethig K, Heublein B, Kutschka I, et al. Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitive C-reactive protein is associated with progressive luminal obstruction. Circulation. 2000;102:III233–III236
  164. Raichlin E, McConnell JP, Bae JH, et al. Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients. Transplantation. 2008;85:963–968
  165. Raichlin ER, McConnell JP, Lerman A, et al. Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy. J Heart Lung Transplant. 2007;26:826–833
  166. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111:363–368
  167. Raichlin E, Kushwaha SS, Lennon RJ, et al. Features of cardiac allograft coronary endothelial dysfunction. Am J Cardiol. 2009;103:1154–1158
  168. Hollenberg SM, Klein LW, Parrillo JE, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation. 2001;104:3091–3096
  169. Davis SF, Yeung AC, Meredith IT, et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation. 1996;93:457–462
  170. Sudhir K, MacGregor JS, DeMarco T, et al. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Circulation. 1994;90:3018–3023
  171. Abraham RT, Karnitz LM, Burns LA, et al. Proximal signals and the control of S-phase entry in interleukin-2-stimulated T lymphocytes. Adv Exp Med Biol. 1994;365:197–210
  172. Edwards BS, Hunt SA, Fowler MB, et al. Effect of cyclosporine on plasma endothelin levels in humans after cardiac transplantation. Am J Cardiol. 1991;67:782–784
  173. Diederich D, Skopec J, Diederich A, et al. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension. 1994;23:957–961
  174. Diederich D, Yang Z, Luscher TF. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol. 1992;2:1291–1297
  175. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. J Am Med Assoc. 1989;261:3607–3609
  176. Koskinen PK, Nieminen MS, Krogerus LA, et al. Cytomegalovirus infection accelerates cardiac allograft vasculopathy: correlation between angiographic and endomyocardial biopsy findings in heart transplant patients. Transpl Int. 1993;6:341–347
  177. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev. 2000;13:83–121[table of contents]
  178. Hussain T, Burch M, Fenton MJ, et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation. 2007;115:1798–1805
  179. Bonaros NE, Kocher A, Dunkler D, et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation. 2004;77:890–897
  180. Zakliczynski M, Krynicka-Mazurek A, Pyka L, et al. The influence of cytomegalovirus infection, confirmed by pp65 Antigen presence, on the development of cardiac allograft vasculopathy. Transplant Proc. 2007;39:2866–2869
  181. Ramzy D, Rao V, Brahm J, et al. Cardiac allograft vasculopathy: a review. Can J Surg. 2005;48:319–327
  182. Gao SZ, Alderman EL, Schroeder JS, et al. Progressive coronary luminal narrowing after cardiac transplantation. Circulation. 1990;82:IV269–IV275
  183. Julius BK, Attenhofer Jost CH, Sutsch G, et al. Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation. Transplantation. 2000;69:847–853
  184. Rickenbacher PR, Pinto FJ, Chenzbraun A, et al. Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol. 1995;25:171–177
  185. Kushwaha SS, Narula J, Narula N, et al. Pattern of changes over time in myocardial blood flow and microvascular dilator capacity in patients with normally functioning cardiac allografts. Am J Cardiol. 1998;82:1377–1381
  186. Sharples LD, Jackson CH, Parameshwar J, et al. Diagnostic accuracy of coronary angiography and risk factors for post-heart-transplant cardiac allograft vasculopathy. Transplantation. 2003;76:679–682
  187. Klauss V, Mudra H, Uberfuhr P, et al. Intraindividual variability of cardiac allograft vasculopathy as assessed by intravascular ultrasound. Am J Cardiol. 1995;76:463–466
  188. Amital A, Shitrit D, Raviv Y, et al. Development of malignancy following lung transplantation. Transplantation. 2006;81:547–551
  189. Fedak PW, Rao V, Verma S, et al. Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation. J Thorac Cardiovasc Surg. 2005;129:407–415
  190. Ross H, Hendry P, Dipchand A, et al. Canadian Cardiovascular Society Consensus Conference on Cardiac Transplantation. Can J Cardiol. 2003;19:620–654
  191. Nair A, Kuban BD, Tuzcu EM, et al. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation. 2002;106:2200–2206
  192. Nair A, Kuban BD, Obuchowski N, et al. Assessing spectral algorithms to predict atherosclerotic plaque composition with normalized and raw intravascular ultrasound data. Ultrasound Med Biol. 2001;27:1319–1331
  193. Nasu K, Tsuchikane E, Katoh O, et al. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol. 2006;47:2405–2412[Epub 2006 May 30]
  194. Raichlin E, Bae JH, Kushwaha SS, et al. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol. 2009;53:1279–1286
  195. Massy ZA, Guijarro C, Wiederkehr MR, et al. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int. 1996;49:518–524
  196. Miyagawa-Hayashino A, Tsuruyama T, Haga H, et al. Arteriopathy in chronic allograft rejection in liver transplantation. Liver Transplant. 2004;10:513–519
  197. Bacon CR, Davenport AP. Endothelin receptors in human coronary artery and aorta. Br J Pharmacol. 1996;117:986–992
  198. Pamboukian SV, Costanzo MR. Transplant coronary vasculopathy. Curr Treat Options Cardiovasc Med. 2001;3:55–63
  199. Bolad IA, Robinson DR, Webb C, et al. Impaired left ventricular systolic function early after heart transplantation is associated with cardiac allograft vasculopathy. Am J Transplant. 2006;6:161–168
  200. Benza RL, Zoghbi GJ, Tallaj J, et al. Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. J Am Coll Cardiol. 2004;43:1973–1981
  201. Jonas M, Fang JC, Wang JC, et al. In-stent restenosis and remote coronary lesion progression are coupled in cardiac transplant vasculopathy but not in native coronary artery disease. J Am Coll Cardiol. 2006;48:453–461[Epub 2006 July 12]
  202. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621–627
  203. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 2003;107:93–97
  204. Mehra MR, Ventura HO, Smart FW, et al. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol. 1995;75:853–854
  205. Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med. 1993;328:164–170
  206. Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002;359:1108–1113
  207. Shirakawa I, Sata M, Saiura A, et al. Atorvastatin attenuates transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation. Biomed Pharmacother. 2007;61:154–159
  208. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a trial of pravastatin in heart transplant recipients. J Heart Lung Transplant. 2005;24:1736–1740
  209. Sipahi I, Starling RC. Cardiac allograft vasculopathy: an update. Heart Fail Clin. 2007;3:87–95
  210. Segovia J, Gomez-Bueno M, Alonso-Pulpon L. Treatment of allograft vasculopathy in heart transplantation. Exp Opin Pharmacother. 2006;7:2369–2383
  211. Lubitz SA, Pinney S, Wisnivesky JP, et al. Statin therapy associated with a reduced risk of chronic renal failure after cardiac transplantation. J Heart Lung Transplant. 2007;26:264–272
  212. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation. 2007;116:2726–2733
  213. Mudge GH. Sirolimus and cardiac transplantation: is it the “magic bullet”?. Circulation. 2007;116:2666–2668
  214. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694–2700
  215. Raichlin E, Prasad A, Kremers WK, et al. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared to calcineurin-inhibitors in stable cardiac transplant recipients. Eur Heart J. 2009;30:1356–1363
  216. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–940
  217. Raichlin E, Bae JH, Kushwaha SS, et al. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol. 2009;53:1279–1286
  218. Lobach NE, Pollock-Barziv SM, West LJ, et al. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant. 2005;24:184–189
  219. Walker K, Skelton H, Smith K. Cutaneous lesions showing giant yeast forms of Blastomyces dermatitidis. J Cutan Pathol. 2002;29:616–618
  220. Masri K, Mahon N, Rosario A, et al. Reactive hemophagocytic syndrome associated with disseminated histoplasmosis in a heart transplant recipient. J Heart Lung Transplant. 2003;22:487–491
  221. Jastrzebski D, Zakliczynski M, Siola M, et al. Lower respiratory tract infections in patients during hospital stay after heart transplantation. Ann Transplant. 2003;8:37–39
  222. Kendall JB, Hart CA, Pennefather SH, et al. Infection control measures for adult cardiac surgery in the UK—a survey of current practice. J Hosp Infect. 2003;54:174–178
  223. Kriaras I, Michalopoulos A, Turina M, et al. Evolution of antimicrobial prophylaxis in cardiovascular surgery. Eur J Cardio Thorac Surg. 2000;18:440–446
  224. Parry GW, Holden SR, Shabbo FP. Antibiotic prophylaxis for cardiac surgery: current United Kingdom practice. Br Heart J. 1993;70:585–586
  225. Casewell MW. The nose: an underestimated source of Staphylococcus aureus causing wound infection. J Hosp Infect. 1998;40(suppl B):S3–S11
  226. Cimochowski GE, Harostock MD, Brown R, et al. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg. 2001;71:1572–1578[Discussion 1578-9]
  227. Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation. 2006;82:S4–S8
  228. Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation. 2006;82:398–405
  229. Noble S, Faulds D. Ganciclovir (An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients). Drugs. 1998;56:115–146
  230. Cooper DK, Novitzky D, Schlegel V, et al. Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation. J Heart Lung Transplant. 1991;10:656–662[Discussion 662-3]
  231. Couchoud C, Cucherat M, Haugh M, et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation. 1998;65:641–647
  232. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antivir Res. 2006;71:154–163
  233. Nankivell BJ, Malouf MA, Russ GR, et al. Maintenance therapy with oral ganciclovir after treatment of cytomegalovirus infection. Clin Transpl. 1998;12:270–273
  234. Gane E, Saliba F, Valdecasas GJ, et al. Randomised Trial of Efficacy and Safety of Oral Ganciclovir in the Prevention of Cytomegalovirus Disease in Liver-Transplant Recipients (Oral Ganciclovir International Transplantation Study Group). [corrected] Lancet. 1997;350:1729–1733
  235. Devyatko E, Zuckermann A, Ruzicka M, et al. Preemptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant. 2004;23:1277–1282
  236. Baldanti F, Simoncini L, Sarasini A, et al. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation. 1998;66:324–329
  237. Drew WL, Paya CV, Cytomegalovirus EV. (CMV) resistance to antivirals. Am J Transplant. 2001;1:307–312
  238. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645–649
  239. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27-29 February 2004 Herpes. 2004;11:77–86
  240. Fiddian P, Sabin CA, Griffiths PD. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J Infect Dis. 2002;186(suppl 1):S110–S115
  241. Baran DA, Alwarshetty MM, Alvi S, et al. Is toxoplasmosis prophylaxis necessary in cardiac transplantation? (Long-term follow-up at two transplant centers). J Heart Lung Transplant. 2006;25:1380–1382
  242. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis. 2001;33:1397–1405
  243. Orr KE, Gould FK, Short G, et al. Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years. J Infect. 1994;29:249–253
  244. Playford EG, Webster AC, Sorell TC, et al. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev. 2004;CD004291
  245. Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323:1767–1769
  246. Penn I. Malignant melanoma in organ allograft recipients. Transplantation. 1996;61:274–278
  247. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005;352:1371–1373
  248. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581–589
  249. Veness MJ. Cardiac transplant-related cutaneous malignancies in an Australian recipient: immunosuppression, friend or foe?. Clin Oncol (R Coll Radiol). 1998;10:194–197
  250. Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer. 1999;85:1758–1764
  251. Lindelof B, Sigurgeirsson B, Gabel H, et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143:513–519
  252. Gjersvik P, Hansen S, Moller B, et al. Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients?. Transpl Int. 2000;13(suppl 1):S380–S381
  253. Tiu J, Li H, Rassekh C, et al. Molecular basis of posttransplant squamous cell carcinoma: the potential role of cyclosporine A in carcinogenesis. Laryngoscope. 2006;116:762–769
  254. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80:883–889
  255. Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc. 2003;35:25S–34S
  256. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transpl. 2004;18:446–449
  257. Otley CC, Maragh SL. Reduction of immunosuppression for transplant-associated skin cancer: rationale and evidence of efficacy. Dermatol Surg. 2005;31:163–168
  258. Otley CC, Berg D, Ulrich C, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol. 2006;154:395–400
  259. Otley CC, Griffin MD, Charlton MR, et al. Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks. Br J Dermatol. 2007;157:1183–1188
  260. Tavadia S, Dawn G, Payne C, et al. Skin-cancer awareness in Scottish cardiac transplant recipients. Clin Exp Dermatol. 2006;31:354–357
  261. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol. 2005;152:518–523
  262. McNamara IR, Muir J, Galbraith AJ. Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant. 2002;21:1201–1205
  263. Goldstein DJ, Williams DL, Oz MC, et al. Novo solid malignancies after cardiac transplantation. Ann Thorac Surg. 1995;60:1783–1789
  264. Pham SM, Kormos RL, Landreneau RJ, et al. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg. 1995;60:1623–1626
  265. Penn I. Tumors after renal and cardiac transplantation. Hematol/Oncol Clin North Am. 1993;7:431–445
  266. Penn I, Hammond W, Brettschneider L, et al. Malignant lymphomas in transplantation patients. Transplant Proc. 1969;1:106–112
  267. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:583–587
  268. Borenstein J, Pezzella F, Gatter KC. Plasmablastic lymphomas may occur as post-transplant lymphoproliferative disorders. Histopathology. 2007;51:774–777
  269. Pitman SD, Rowsell EH, Cao JD, et al. Anaplastic large cell lymphoma associated with Epstein–Barr virus following cardiac transplant. Am J Surg Pathol. 2004;28:410–415
  270. Salama S. Primary “cutaneous” T-cell anaplastic large cell lymphoma, CD30+, neutrophil-rich variant with subcutaneous panniculitic lesions, in a post-renal transplant patient: report of unusual case and literature review. Am J Dermatopathol. 2005;27:217–223
  271. Tsao L, Chu KE, Bhagat G, et al. Development of hairy cell leukemia in a patient after cardiac transplantation. Leuk Lymph. 2006;47:361–363
  272. Tsao L, Draoua HY, Mansukhani M, et al. EBV-associated, extranodal NK-cell lymphoma, nasal type of the breast, after heart transplantation. Mod Pathol. 2004;17:125–130
  273. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol. 1988;133:173–192
  274. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per SE?. Transplantation. 2003;76:984–988
  275. Gao SZ, Chaparro SV, Perlroth M, et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant. 2003;22:505–514
  276. Aull MJ, Buell JF, Trofe J, et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation. 2004;78:1676–1682
  277. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein–Barr virus: a distinct entity?. J Clin Oncol. 1998;16:2052–2059
  278. Dotti G, Fiocchi R, Motta T, et al. Epstein–Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation. 2000;69:827–833
  279. Smith JM, Corey L, Healey PJ, et al. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein–Barr virus infection than younger renal transplant recipients. Transplantation. 2007;83:1423–1428
  280. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis. 2001;3:70–78
  281. Darenkov IA, Marcarelli MA, Basadonna GP, et al. Reduced incidence of Epstein–Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation. 1997;64:848–852
  282. Davis CL, Harrison KL, McVicar JP, et al. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transpl. 1995;9:53–59
  283. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, et al. Quantitative oropharyngeal Epstein–Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis. 1992;166:986–994
  284. Nart D, Nalbantgil S, Yagdi T, et al. Primary cardiac lymphoma in a heart transplant recipient. Transplant Proc. 2005;37:1362–1364
  285. Ouseph R, Denny DM, Erbeck KM. Lymphoproliferative disease seen as a cardiac mass after orthotopic heart transplantation. J Am Soc Echocardiogr. 1998;11:758–760
  286. Bregman SG, Yeaney GA, Greig BW, et al. Subcutaneous panniculitic T-cell lymphoma in a cardiac allograft recipient. J Cutan Pathol. 2005;32:366–370
  287. Samolitis NJ, Bharadwaj JS, Weis JR, et al. Post-transplant lymphoproliferative disorder limited to the skin. J Cutan Pathol. 2004;31:453–457
  288. Lamba M, Jabi M, Padmore R, et al. Isolated pleural PTLD after cardiac transplantation. Cardiovasc Pathol. 2002;11:346–350
  289. Rolland SL, Seymour RA, Wilkins BS, et al. Post-transplant lymphoproliferative disorders presenting as gingival overgrowth in patients immunosuppressed with ciclosporin (A report of two cases). J Clin Periodontol. 2004;31:581–585
  290. Boilson BA, Miller DV, Pereira NL. Late allograft failure after heart transplantation: 2 unusual cases. J Heart Lung Transplant. 2008;27:1050–1054
  291. Siddiqui MT, Reddy VB, Castelli MJ, et al. Role of fine-needle aspiration in clinical management of transplant patients. Diagn Cytopathol. 1997;17:429–435
  292. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11(suppl 1):113–116
  293. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant. 2005;5:2901–2906
  294. Everly MJ, Bloom RD, Tsai DE, et al. Posttransplant lymphoproliferative disorder. Ann Pharmacother. 2007;41:1850–1858
  295. Haddad E, Paczesny S, Leblond V, et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood. 2001;97:1590–1597
  296. Trappe R, Riess H, Babel N, et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation. 2007;83:912–918
  297. Preiksaitis JK. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis. 2004;39:1016–1023
  298. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123–1131

 The authors have no conflicts to disclose.

PII: S0146-2806(09)00124-8

doi: 10.1016/j.cpcardiol.2009.09.001

Current Problems in Cardiology
Volume 35, Issue 1 , Pages 8-64 , January 2010

Article Tools

* Image Usage & Resolution